deltatrials
Terminated PHASE2 INTERVENTIONAL 1-arm NCT02524275

Docetaxel and Capecitabine With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Phase II Study of Docetaxel and Capecitabine in Advanced Squamous Cell Carcinoma of the Head and Neck

Sponsor: University of Nebraska

Conditions Head and Neck Squamous Cell Carcinoma
Interventions Capecitabine Docetaxel Quality-of-Life Assessment Questionnaire Administration
Updated 14 times since 2017 Last updated: Aug 25, 2023 Started: Mar 30, 2015 Primary completion: Oct 28, 2021 Completion: Oct 28, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

low enrollment

Other terminated trials from University of Nebraska

See all terminations from University of Nebraska

Other Head and Neck Squamous Cell Carcinoma trials with similar outcome

Browse all Head and Neck Squamous Cell Carcinoma trials

This PHASE2 trial investigates Head and Neck Squamous Cell Carcinoma and is currently terminated or withdrawn. University of Nebraska leads this study, which shows 14 recorded versions since 2015 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Feb 2018 · 12 months · monthly snapshot~Feb 2018 – ~Jun 2018 · 4 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Aug 2019 · 13 months · monthly snapshot~Aug 2019 – ~Jul 2020 · 11 months · monthly snapshot~Jul 2020 – ~Jan 2021 · 6 months · monthly snapshot~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshot~Sep 2021 – ~Dec 2021 · 3 months · monthly snapshot~Dec 2021 – ~Sep 2022 · 9 months · monthly snapshot~Sep 2022 – ~Oct 2023 · 13 months · monthly snapshot~Oct 2023 – ~Jul 2024 · 9 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

14 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  3. Oct 2023 — Jul 2024 [monthly]

    Terminated PHASE2

  4. Sep 2022 — Oct 2023 [monthly]

    Terminated PHASE2

  5. Dec 2021 — Sep 2022 [monthly]

    Terminated PHASE2

    Status: Recruiting → Terminated

▶ Show 9 earlier versions

  1. Sep 2021 — Dec 2021 [monthly]

    Recruiting PHASE2

  2. Jan 2021 — Sep 2021 [monthly]

    Recruiting PHASE2

  3. Jul 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

  4. Aug 2019 — Jul 2020 [monthly]

    Recruiting PHASE2

  5. Jul 2018 — Aug 2019 [monthly]

    Recruiting PHASE2

  6. Jun 2018 — Jul 2018 [monthly]

    Recruiting PHASE2

  7. Feb 2018 — Jun 2018 [monthly]

    Recruiting PHASE2

  8. Feb 2017 — Feb 2018 [monthly]

    Recruiting PHASE2

  9. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE2

    First recorded

Mar 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • University of Nebraska
Data source: University of Nebraska

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations